Treatment-Resistant IBD Patients May Benefit from New Combination Therapy

Promising New Treatment for IBD

Recent research has unveiled that a new combination antibody therapy could provide significant benefits to patients suffering from treatment-resistant inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis. Conducted by Johnson & Johnson, the clinical trials demonstrated that the fixed-dose co-antibody therapy, known as JNJ-4804, showed better outcomes than existing therapies in patients who had previously failed other treatments.

Understanding IBD and Its Challenges

IBD is an umbrella term that encompasses two major conditions: ulcerative colitis (UC) and Crohn's disease, affecting over 4.9 million people globally. These diseases cause chronic inflammation of the digestive tract and are characterized by severe symptoms, including abdominal pain and diarrhea. Currently, there is no cure for IBD, and treatments mainly focus on reducing inflammation and alleviating symptoms through medications, lifestyle changes, and sometimes surgery. However, it is estimated that 30% to 50% of patients do not respond to available therapies.

Researchers presented their findings at the Digestive Disease Week® 2026, highlighting the urgent need for new treatment approaches, especially for patients who have not seen success with existing options.

The Clinical Trials

The two Phase 2b clinical trials—DUET-Crohn's and DUET-UC—were conducted to evaluate the efficacy of JNJ-4804, which combines guselkumab, an anti-IL-23 therapy, and golimumab, an anti-TNF antibody. The trials involved 693 participants for Crohn's disease and 572 for ulcerative colitis, who were divided into groups receiving either a placebo, just golimumab, just guselkumab, or the new combination therapy.

Results indicated that patients who had failed treatments benefited significantly from the combination therapy. At 48 weeks, those on JNJ-4804 showed improved outcomes compared to those receiving individual therapies, with results signaling this therapy could set new benchmarks in treating refractory IBD.

Expert Insights on the Findings

According to Dr. Bruce E. Sands, a leading gastroenterologist involved in the studies, this new combination represents an important step forward in IBD treatment, emphasizing the need for therapies that address multiple pathways involved in these complex diseases. Dr. Maria T. Abreu, who led the UC study, expressed that patients selected for the trials already faced challenging treatment scenarios, having previously been treated with various advanced therapies.

“It’s actually possible that the immune system changes because now if you suppress only one thing, the immune system tries to find a way around it to continue this inflammatory response,” said Dr. Abreu, highlighting the complexities involved in treating IBD.

Looking Forward

The potential approval of JNJ-4804 is still a few years away, as further phase 3 studies are needed to validate these findings. Dr. Sands predicts these studies will not be completed before two-and-a-half to three years, delaying the availability of this promising therapy for many IBD sufferers.

Implications for Future Treatments

Dr. Alyssa Parian, who was not directly involved in the research, noted that the dual therapy approach is already being utilized in clinical practices for patients with severe refractory IBD. She believes that combining therapies targeting different inflammatory pathways could lead to better management of the disease without increasing safety risks.

“Seeing that this approach may be able to ‘outsmart’ the immune system is very exciting,” Dr. Parian remarked.

With these promising developments, the landscape for IBD treatments may soon shift, offering hope to those enduring the challenges of this chronic condition.